Medifast Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

Wall Street analysts have given Medifast a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medifast wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medifast saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 273,500 shares, a decline of 36.0% from the March 15th total of 427,400 shares. Based on an average daily trading volume, of 126,800 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.5% of the company's shares are sold short.
View Medifast's Short Interest.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Medifast.

Medifast, Inc. (NYSE:MED) posted its quarterly earnings results on Tuesday, May, 4th. The specialty retailer reported $3.46 EPS for the quarter, topping the consensus estimate of $2.72 by $0.74. The specialty retailer had revenue of $340.70 million for the quarter, compared to analysts' expectations of $279.12 million. Medifast had a net margin of 11.27% and a trailing twelve-month return on equity of 80.07%. The firm's quarterly revenue was up 90.9% compared to the same quarter last year.
View Medifast's earnings history.

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MED stock has increased by 317.7% and is now trading at $294.21.
View which stocks have been most impacted by COVID-19.

Medifast declared a quarterly dividend on Friday, March 19th. Shareholders of record on Tuesday, March 30th will be paid a dividend of $1.42 per share on Thursday, May 6th. This represents a $5.68 annualized dividend and a yield of 1.93%. The ex-dividend date is Monday, March 29th. This is an increase from Medifast's previous quarterly dividend of $1.13.
View Medifast's dividend history.

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 1.93%. Medifast does not yet have a strock track record of dividend growth. The dividend payout ratio of Medifast is 95.30%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Medifast will have a dividend payout ratio of 54.51% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

Medifast updated its FY 2021 earnings guidance on Tuesday, May, 11th. The company provided EPS guidance of 12.690-14.140 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.110. The company issued revenue guidance of $1.40 billion-$1.48 billion, compared to the consensus revenue estimate of $1.19 billion.

3 brokers have issued 1 year price targets for Medifast's shares. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's share price to reach $353.33 in the next year. This suggests a possible upside of 20.1% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medifast include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), USANA Health Sciences (USNA), Veru (VERU), Revlon (REV) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.42%), Principal Financial Group Inc. (1.72%), Acadian Asset Management LLC (1.18%), Russell Investments Group Ltd. (0.49%), Ingalls & Snyder LLC (0.39%) and Rhumbline Advisers (0.29%). Company insiders that own Medifast stock include Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Landscape Capital Management L.L.C., Victory Capital Management Inc., GSA Capital Partners LLP, Acadian Asset Management LLC, Russell Investments Group Ltd., Robeco Institutional Asset Management B.V., Los Angeles Capital Management LLC, and Ingalls & Snyder LLC. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast or view top insider-selling stocks.

MED stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BI Asset Management Fondsmaeglerselskab A S, Principal Financial Group Inc., Blueshift Asset Management LLC, Hillsdale Investment Management Inc., Rowland & Co. Investment Counsel ADV, Versor Investments LP, and Seizert Capital Partners LLC.
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $294.21.

Medifast has a market capitalization of $3.46 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis.

Medifast employs 713 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]